LOGIN  |  REGISTER
Astria Therapeutics
Amneal Pharmaceuticals

Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

February 06, 2025 | Last Trade: US$63.85 0.86 1.37
  • Financial release accessible online

BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information:

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below. 

Direct link to 3Q FY25 Earnings Release: https://haemonetics.gcs-web.com/static-files/36134646-a371-4076-87b9-26673f9f10f3

A replay of the conference call and webcast will be available for one year beginning on February 6, 2025, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:                                                     

 

Olga Guyette, Vice President-Investor Relations & Treasury     

David Trenk, Manager-Investor Relations

(781) 356-9763                                                     

(203) 733-4987

This email address is being protected from spambots. You need JavaScript enabled to view it.                           

This email address is being protected from spambots. You need JavaScript enabled to view it.  

  

Media Contact:   

 

Josh Gitelson, Sr. Director-Global Communications       

 

(781) 356-9776

 

This email address is being protected from spambots. You need JavaScript enabled to view it. 

 
Recursion

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page